These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29582414)

  • 1. The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception.
    Hill R; Disney A; Conibear A; Sutcliffe K; Dewey W; Husbands S; Bailey C; Kelly E; Henderson G
    Br J Pharmacol; 2018 Jul; 175(13):2653-2661. PubMed ID: 29582414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine.
    Kudla L; Bugno R; Skupio U; Wiktorowska L; Solecki W; Wojtas A; Golembiowska K; Zádor F; Benyhe S; Buda S; Makuch W; Przewlocka B; Bojarski AJ; Przewlocki R
    Br J Pharmacol; 2019 Dec; 176(23):4434-4445. PubMed ID: 31347704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available μ-opioid receptor number.
    Singleton S; Baptista-Hon DT; Edelsten E; McCaughey KS; Camplisson E; Hales TG
    Br J Pharmacol; 2021 Apr; 178(8):1855-1868. PubMed ID: 33555037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates.
    Ding H; Kiguchi N; Perrey DA; Nguyen T; Czoty PW; Hsu FC; Zhang Y; Ko MC
    Br J Anaesth; 2020 Oct; 125(4):596-604. PubMed ID: 32819621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels.
    Yudin Y; Rohacs T
    Br J Pharmacol; 2019 Sep; 176(17):3110-3125. PubMed ID: 31074038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics simulation.
    Liao S; Tan K; Floyd C; Bong D; Pino MJ; Wu C
    Life Sci; 2021 Mar; 269():119026. PubMed ID: 33444617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
    Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
    Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Dynamics Simulations to Investigate How PZM21 Affects the Conformational State of the μ-Opioid Receptor Upon Activation.
    Zhao Z; Huang T; Li J
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl depression of respiration: Comparison with heroin and morphine.
    Hill R; Santhakumar R; Dewey W; Kelly E; Henderson G
    Br J Pharmacol; 2020 Jan; 177(2):254-266. PubMed ID: 31499594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based discovery of opioid analgesics with reduced side effects.
    Manglik A; Lin H; Aryal DK; McCorvy JD; Dengler D; Corder G; Levit A; Kling RC; Bernat V; Hübner H; Huang XP; Sassano MF; Giguère PM; Löber S; Da Duan ; Scherrer G; Kobilka BK; Gmeiner P; Roth BL; Shoichet BK
    Nature; 2016 Sep; 537(7619):185-190. PubMed ID: 27533032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the potential of novel and classical opioids to induce respiratory depression in mice.
    Hill R; Sanchez J; Lemel L; Antonijevic M; Hosking Y; Mistry SN; Kruegel AC; Javitch JA; Lane JR; Canals M
    Br J Pharmacol; 2023 Dec; 180(24):3160-3174. PubMed ID: 37489013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat.
    Araldi D; Ferrari LF; Levine JD
    Neuroscience; 2018 Dec; 394():60-71. PubMed ID: 30342200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of β-arrestin-2 in short- and long-term opioid tolerance in the dorsal root ganglia.
    Muchhala KH; Jacob JC; Dewey WL; Akbarali HI
    Eur J Pharmacol; 2021 May; 899():174007. PubMed ID: 33705801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: correlation with μ-opioid receptor internalization.
    Silva-Moreno A; Gonzalez-Espinosa C; León-Olea M; Cruz SL
    Eur J Pharmacol; 2012 Jan; 674(2-3):239-47. PubMed ID: 22079772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
    Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
    Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Evaluation of Novel Biased μ-Opioid-Receptor (μOR) Agonists.
    Ma M; Sun J; Li M; Yu Z; Cheng J; Zhong B; Shi W
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30641969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.
    Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M
    Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
    Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
    Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Biological Evaluation of Novel Biased Mu-Opioid Receptor Agonists.
    Guo Y; Yu R; Zhang T; Ren F; Yu Z; Cheng J; Jia H; Shi W; Zhang Y
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38998913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.